Do analysts rate BBLG or BIOL?

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BBLG or BIOL more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts rate BIOL or PTHL?

Given BIOLASE's higher possible upside, research analysts clearly believe BIOLASE is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BIOL or PTHL?

Pheton has lower revenue, but higher earnings than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Pheton $305.22K 6.04 -$660K N/A N/A

Is BIOL or PTHL more profitable?

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Pheton N/A N/A N/A

Do analysts prefer BIOL or IVF?

INVO Fertility has a consensus price target of $20.00, indicating a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts clearly believe INVO Fertility is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, BIOL or IVF?

BIOLASE has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A INVO Fertility $6.84M 0.27 -$25.13M -$352.18 N/A

Is BIOL or IVF more profitable?

BIOLASE has a net margin of -41.65% compared to INVO Fertility's net margin of -183.75%. INVO Fertility's return on equity of -420.62% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% INVO Fertility -183.75% -420.62% -45.21%

Do analysts recommend BIOL or AEMD?

Given BIOLASE's higher possible upside, equities analysts plainly believe BIOLASE is more favorable than Aethlon Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BIOL or AEMD more profitable?

Aethlon Medical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Aethlon Medical's return on equity of -137.73% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Aethlon Medical N/A -137.73% -105.87%

Do analysts rate VBIO or BIOL?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

BIOLASE (BIOL) Competitors

Compare

BIOL vs. BBLG, PTHL, IVF, AEMD, and VBIO

Should you buy BIOLASE stock or one of its competitors? MarketBeat compares BIOLASE with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BIOLASE include Bone Biologics (BBLG), Pheton (PTHL), INVO Fertility (IVF), Aethlon Medical (AEMD), and Valion Bio, Inc. Common Stock (VBIO). These companies are all part of the "medical equipment" industry.

How does BIOLASE compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by company insiders. Comparatively, 0.3% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bone Biologics has higher earnings, but lower revenue than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Bone Biologics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -50.47% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Given BIOLASE's higher probable upside, analysts plainly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Bone Biologics' average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
BIOLASE	Neutral

Summary

Bone Biologics beats BIOLASE on 9 of the 11 factors compared between the two stocks.

How does BIOLASE compare to Pheton?

BIOLASE (NASDAQ:BIOL) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Given BIOLASE's higher possible upside, research analysts clearly believe BIOLASE is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Pheton	N/A	N/A	N/A

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Pheton	Neutral

Pheton has lower revenue, but higher earnings than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Pheton	$305.22K	6.04	-$660K	N/A	N/A

8.8% of BIOLASE shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

Summary

Pheton beats BIOLASE on 6 of the 10 factors compared between the two stocks.

How does BIOLASE compare to INVO Fertility?

BIOLASE (NASDAQ:BIOL) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market.

BIOLASE has a net margin of -41.65% compared to INVO Fertility's net margin of -183.75%. INVO Fertility's return on equity of -420.62% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
INVO Fertility	-183.75%	-420.62%	-45.21%

INVO Fertility has a consensus price target of $20.00, indicating a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts clearly believe INVO Fertility is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled INVO Fertility'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
INVO Fertility	Neutral

BIOLASE has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
INVO Fertility	$6.84M	0.27	-$25.13M	-$352.18	N/A

Summary

INVO Fertility beats BIOLASE on 8 of the 12 factors compared between the two stocks.

How does BIOLASE compare to Aethlon Medical?

BIOLASE (NASDAQ:BIOL) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 0.7% of Aethlon Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aethlon Medical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Aethlon Medical's return on equity of -137.73% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Aethlon Medical	N/A	-137.73%	-105.87%

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Aethlon Medical'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Aethlon Medical	Neutral

BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Given BIOLASE's higher possible upside, equities analysts plainly believe BIOLASE is more favorable than Aethlon Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aethlon Medical has lower revenue, but higher earnings than BIOLASE. Aethlon Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$14.69	N/A

Summary

Aethlon Medical beats BIOLASE on 7 of the 12 factors compared between the two stocks.

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for BIOLASE. Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
BIOLASE	Neutral

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than BIOLASE. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$6.68	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
BIOLASE	-41.65%	-1,782.73%	-55.31%

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Valion Bio, Inc. Common Stock beats BIOLASE on 8 of the 13 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Dental equipment & supplies Industry	Medical Sector	NASDAQ Exchange
Market Cap	$581K	$3.92M	$6.81B	$12.41B
Dividend Yield	N/A	N/A	2.67%	9.39%
P/E Ratio	0.00	N/A	27.00	24.19
Price / Sales	N/A	0.09	517.32	92.93
Price / Cash	N/A	N/A	26.68	47.25
Price / Book	N/A	0.01	10.67	6.26
Net Income	-$20.63M	-$60.92M	$3.60B	$331.76M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
BBLG Bone Biologics	0.4561 of 5 stars	$1.24 -1.6%	N/A	-60.8%	$2.26M	N/A	N/A	2
PTHL Pheton	N/A	$0.33 +0.7%	N/A	-98.7%	$2.15M	$305.22K	N/A	11	Gap Down
IVF INVO Fertility	1.7436 of 5 stars	$1.13 flat	$20.00 +1,669.9%	-99.0%	$2.02M	$6.84M	N/A	10
AEMD Aethlon Medical	0.3079 of 5 stars	$0.69 +0.4%	N/A	-95.3%	$1.62M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. BBLG, PTHL, IVF, AEMD, and VBIO

How does BIOLASE compare to Bone Biologics?

Summary

How does BIOLASE compare to Pheton?

Summary

How does BIOLASE compare to INVO Fertility?

Summary

How does BIOLASE compare to Aethlon Medical?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. BBLG, PTHL, IVF, AEMD, and VBIO

How does BIOLASE compare to Bone Biologics?

Do institutionals and insiders believe in BBLG or BIOL?

Which has higher earnings and valuation, BBLG or BIOL?

Which has more risk & volatility, BBLG or BIOL?

Is BBLG or BIOL more profitable?

Do analysts rate BBLG or BIOL?

Does the media favor BBLG or BIOL?

Summary

How does BIOLASE compare to Pheton?

Do analysts rate BIOL or PTHL?

Is BIOL or PTHL more profitable?

Does the media prefer BIOL or PTHL?

Which has higher valuation & earnings, BIOL or PTHL?

Do institutionals & insiders have more ownership in BIOL or PTHL?

Which has more volatility and risk, BIOL or PTHL?

Summary

How does BIOLASE compare to INVO Fertility?

Do institutionals and insiders believe in BIOL or IVF?

Which has more volatility & risk, BIOL or IVF?

Is BIOL or IVF more profitable?

Do analysts prefer BIOL or IVF?

Does the media refer more to BIOL or IVF?

Which has preferable valuation & earnings, BIOL or IVF?

Summary

How does BIOLASE compare to Aethlon Medical?

Do institutionals & insiders hold more shares of BIOL or AEMD?

Is BIOL or AEMD more profitable?

Does the media prefer BIOL or AEMD?

Which has more volatility & risk, BIOL or AEMD?

Do analysts recommend BIOL or AEMD?

Which has better valuation and earnings, BIOL or AEMD?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Does the media favor VBIO or BIOL?

Which has higher valuation and earnings, VBIO or BIOL?

Is VBIO or BIOL more profitable?

Do insiders & institutionals have more ownership in VBIO or BIOL?

Which has more risk & volatility, VBIO or BIOL?

Do analysts rate VBIO or BIOL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools